HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Stada Takes ViruProtect Cold Spray To Vietnam, Launches Austria’s First OTC Triptan

Executive Summary

Stada Arzneimittel is expanding its presence in Vietnam's $2.4bn OTC market and launching Austria's first non-prescription triptan.

You may also be interested in...

People On The Move: Appointments At GSK, Enzymatica And ANSES

The latest European consumer health industry appointments: GSK names Southern Europe head and adds media chief; Enzymatica's new CEO makes early start; and France's ANSES hires risk assessment director.

Sanofi Streamlines European Portfolio With Brand Sale To Stada

Sanofi is pressing ahead with plans to divest up to 150 consumer health brands by selling a portfolio of 16 products marketed in key European countries to Germany's Stada.

People On The Move: Appointments At Stada, CHPA, Valbiotis And DSA

The latest global health and wellness industry appointments: Stada hires Uriach's Roura to lead Spanish OTC business; CHPA elects J&J's Goodridge; Valbiotis brings in Ipsen's Bessy; and Mannatech's Bala joins DSA's board.

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts